Canada markets open in 6 hours 59 minutes

Arcturus Therapeutics Holdings Inc. (ARCT)

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
Add to watchlist
31.00-0.60 (-1.90%)
At close: 04:00PM EDT
31.60 +0.60 (+1.94%)
After hours: 07:44PM EDT

Arcturus Therapeutics Holdings Inc.

10628 Science Center Drive
Suite 250
San Diego, CA 92121
United States
858 900 2660
https://arcturusrx.com

Sector(s)Healthcare
IndustryBiotechnology
Full Time Employees180

Key Executives

NameTitlePayExercisedYear Born
Mr. Joseph E. Payne M.Sc.Founder, President, CEO & Director906.5kN/A1972
Dr. Padmanabh Chivukula Ph.D.Founder, Chief Scientific Officer, COO & Secretary687.5kN/A1979
Mr. Andrew H. Sassine MBACFO & Director687.5kN/A1964
Mr. Lance KurataChief Legal Officer600kN/AN/A
Ms. Neda SafarzadehVice President and Head of IR/PR & MarketingN/AN/AN/A
Ms. Natash O. BowmanChief Human Resources OfficerN/AN/AN/A
Mr. Kevin T. SkolChief Business OfficerN/AN/AN/A
Dr. Juergen Froehlich FCPh, M.D., MBAChief Medical OfficerN/AN/A1956
Dr. Igor Smolenov M.D., Ph.D.Chief Development OfficerN/AN/AN/A
Ms. Roberta DuncanChief Strategy OfficerN/AN/AN/A
Amounts are as of December 31, 2023 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Arcturus Therapeutics Holdings Inc., a late-stage clinical messenger RNA medicines and vaccine company, focuses on the development of infectious disease vaccines and other products within liver and respiratory rare diseases. Its technology platforms include LUNAR lipid-mediated delivery and STARR mRNA. The company is developing ARCT-810 (LUNAR-OTC), a mRNA-based therapeutic candidate, which is in Phase 2 clinical trial for treating ornithine transcarbamylase deficiency; and ARCT-154 (LUNAR-COV19), a mRNA vaccine candidate that is in Phase 3 arm of a Phase 1/2/3 study in Vietnam for the treatment of COVID-19, as well as ARCT-032 (LUNAR-CF), a mRNA therapeutic candidate for cystic fibrosis. Its product pipeline includes, ARCT-2301 for bivalent: ancestral/omicron which is in Phase 3; ARCT-2303 for monovalent that is in Phase 3; ARCT-2138 for quadrivalent which is in Phase 1; and LUNAR-FLU which is in pre-clinical trial. Arcturus Therapeutics Holdings Inc. was founded in 2013 and is headquartered in San Diego, California.

Corporate Governance

Arcturus Therapeutics Holdings Inc.’s ISS Governance QualityScore as of June 1, 2024 is 7. The pillar scores are Audit: 10; Board: 3; Shareholder Rights: 6; Compensation: 8.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.